Clinical trials
Terminated Hypertension trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
263 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2002 | 2 |
| 2003 | 6 |
| 2004 | 6 |
| 2005 | 7 |
| 2006 | 13 |
| 2007 | 20 |
| 2008 | 9 |
| 2009 | 14 |
| 2010 | 8 |
| 2011 | 16 |
| 2012 | 14 |
| 2013 | 19 |
| 2014 | 14 |
| 2015 | 14 |
| 2016 | 8 |
| 2017 | 19 |
| 2018 | 15 |
| 2019 | 16 |
| 2020 | 11 |
| 2021 | 8 |
| 2022 | 11 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 263 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 6 |
| Brigham and Women's Hospital | 4 |
| Novartis | 4 |
| Takeda | 4 |
| University of California, San Francisco | 4 |
| University of Colorado, Denver | 4 |
| Vanderbilt University Medical Center | 4 |
| Boehringer Ingelheim | 3 |
| GlaxoSmithKline | 3 |
| Pfizer | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hypertension | 263 |
| Diabetes Mellitus | 30 |
| Obesity | 20 |
| Cardiovascular Diseases | 18 |
| Diabetes Mellitus, Type 2 | 14 |
| Coronary Artery Disease | 8 |
| Heart Failure | 8 |
| Inflammation | 8 |
| Dyslipidemias | 7 |
| Hypercholesterolemia | 7 |
Trials
Showing 1 to 25 of 263. Each trial links to its page on Pharma Observatory.
163 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.